Clozapine Without REMS: A New Era in Treatment-Resistant Schizophrenia

Course overview

Clozapine remains the gold-standard antipsychotic for individuals with treatment-resistant schizophrenia (TRS), offering superior outcomes in symptom control, suicide prevention, and hospitalization reduction. Despite its unmatched efficacy, clozapine remains underutilized due to complex risk management protocols and concerns about adverse effects, particularly neutropenia. The FDA-approved prescribing information recommends routine absolute neutrophil count surveillance for the duration of therapy. A global expert consensus recommends more individualized monitoring, including cessation of routine ANC checks after two years in stable patients. As regulatory guidance shifts and global consensus supports more individualized monitoring strategies, clinicians must stay informed to balance treatment access with patient safety.